Jesse M Zaretsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4736317/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2016, 165, 35-44.	28.9	2,437
2	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine, 2016, 375, 819-829.	27.0	2,430
3	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports, 2017, 19, 1189-1201.	6.4	1,256
4	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. Cancer Discovery, 2017, 7, 188-201.	9.4	997
5	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	9.4	367
6	PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research, 2016, 4, 194-203.	3.4	321
7	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	28.9	287
8	T cell antigen discovery via trogocytosis. Nature Methods, 2019, 16, 183-190.	19.0	117
9	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunology Research, 2016, 4, 845-857.	3.4	110
10	T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nature Methods, 2019, 16, 191-198.	19.0	103
11	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discovery, 2020, 10, 1140-1157.	9.4	97
12	PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer, 2020, 1, 46-58.	13.2	85
13	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine, 2020, 12, .	12.4	77
14	Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Reports, 2019, 28, 2728-2738.e7.	6.4	65